The business of running medical research outside traditional hospital and clinic settings is poised for sharp growth over the coming decade, according to a new market analysis.
A study published by Healthcare Foresights projects that the global market for decentralized clinical trials will be worth roughly USD 38.3 billion by 2035. The firm estimates the market will expand at a compound annual growth rate of 14.5% over the forecast period.
Decentralized clinical trials refer to drug and treatment studies that move some or all of their activity away from a single central research site. Instead of requiring participants to travel repeatedly to a hospital, these trials lean on tools such as remote monitoring, home visits, and digital data collection to reach patients where they are.
Healthcare Foresights frames its figures as a demand analysis of the market's size, share, and revenue. The headline number — a market approaching USD 38 billion within roughly a decade — signals that researchers, drugmakers, and the technology vendors that support them expect this approach to keep gaining ground.
It is worth noting that the underlying source here is a single market-research forecast. Projections of this kind are estimates built on assumptions about future demand, not guarantees, and the report does not detail the specific drivers behind its numbers in the material provided.
Why it matters: if the forecast holds, it points to a continued shift in how new medicines are tested — one that could make participating in research easier and more accessible for patients who live far from major medical centers.